Armstrong AW, Jayade S, Rege S, Joshi N, Patel V, Kalirai S, Wolin D, Boyle K, Patel D, Seigel L. Evaluating treatment choice in patients with moderate to severe psoriasis in the United States: results from a US patient survey. Dermatol Ther. 2024 Feb;14(2):421-39. doi: 10.1007/s13555-023-01089-6
Li D, Tan R, Hernandez S, Reilly N, Bussberg C, Mansfield C. Patient preferences for unresectable hepatocellular carcinoma treatments: a discrete-choice experiment. Cancers. 2023 Feb 25;15(5):1470. doi: 10.3390/cancers15051470
Menon AP, Moreno B, Meraviglia-Crivelli D, Nonatelli F, Villanueva H, Barainka M, Zheleva A, van Santen HM, Pastor F. Modulating T cell responses by targeting CD3. Cancers. 2023 Feb 13;15(4):1189. doi: 10.3390/cancers15041189
Paller AS, Yosipovitch G, Weidinger S, DiBenedetti D, Whalley D, Gadkari A, Guillemin I, Zhang H, Eckert L, Chao J, Bansal A, Chuang CC, Delevry D. Development, psychometric validation and responder definition of worst itch scale in children with severe atopic dermatitis. Dermatol Ther. 2022 Dec;12(12):2839-50. doi: 10.1007/s13555-022-00804-z
Wyrwich KW, Winnette R, Bender R, Gandhi K, Williams N, Harris N, Nelson L. Validation of the alopecia areata patient priority outcomes (AAPPO) questionnaire in adults and adolescents with alopecia areata. Dermatol Ther. 2022 Jan;12(1):149-66. doi: 10.1007/s13555-021-00648-z
Houghton K, Patil D, Gomez B, Feldman SR. Correlation between change in psoriasis area and severity index and dermatology life quality index in patients with psoriasis: pooled analysis from four phase 3 clinical trials of Secukinumab. Dermatol Ther. 2021 Aug;11(4):1373-84. doi: 10.1007/s13555-021-00564-2
Simpson EL, de Bruin-Weller M, Bansal A, Chen Z, Nelson L, Whalley D, Prescilla R, Guillemin I, Delevry D. Definition of clinically meaningful within-patient changes in POEM and CDLQI in children 6 to 11 years of age with severe atopic dermatitis. Dermatol Ther. 2021 Aug;11(4):1415-22. doi: 10.1007/s13555-021-00543-7
Winnette R, Martin S, Harris N, Deal LS. Development of the alopecia areata patient priority outcomes instrument: a qualitative study. Dermatol Ther. 2021 Apr;11(2):599-613. doi: 10.1007/s13555-021-00508-w
Simpson EL, de Bruin-Weller M, Eckert L, Whalley D, Guillemin I, Reaney M, Chen Z, Nelson L, Qin S, Bansal A, Gadkari A. Responder threshold for Patient-Oriented Eczema Measure (POEM) and Children's Dermatology Life Quality Index (CDLQI) in adolescents with atopic dermatitis. Dermatol Ther. 2019 Dec;9(4):799-805. doi: 10.1007/s13555-019-00333-2
Kuznik A, Bego-Le-Bagousse G, Eckert L, Gadkari A, Simpson E, Graham CN, Miles L, Mastey V, Mahajan P, Sullivan SD. Economic evaluation of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults. Dermatol Ther. 2017 Dec;7(4):493-505. doi: 10.1007/s13555-017-0201-6
Wong-Sefidan I, Byrtek M, Zhou X, Dawson K, Friedberg J, Flowers CR, Zelenetz A, Reid E. Non-clinical factors drive imaging patterns after induction therapy of follicular lymphoma (FL): report from the National LymphoCare Study (NLCS). Poster presented at the 2013 12th International Conference on Malignant Lymphoma; June 2013. Lugano, Switzerland. [abstract] Hematol Oncol. 2013 Jun 17; 31(S1):255.